Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

被引:9
作者
Economopoulou, Panagiota [1 ]
Pantazopoulos, Anastasios [1 ]
Spathis, Aris [2 ]
Kotsantis, Ioannis [1 ]
Kyriazoglou, Anastasios [1 ]
Kavourakis, George [1 ]
Zakopoulou, Roubini [1 ]
Chatzidakis, Ioannis [1 ]
Anastasiou, Maria [1 ]
Prevezanou, Maria [1 ]
Resteghini, Carlo [3 ]
Licitra, Lisa [3 ,4 ]
Bergamini, Cristiana [3 ]
Colombo, Elena [3 ]
Caspani, Francesca [3 ]
Denaro, Nerina [5 ]
Vecchio, Stefania [6 ]
Bonomo, Pierluigi [7 ]
Cossu Rocca, Maria [8 ]
Bertolini, Federica [9 ]
Ferrari, Daris [10 ]
Psyrri, Amanda [1 ]
Bossi, Paolo [11 ]
机构
[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, Athens 12462, Greece
[2] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Pathol 2, Athens 12462, Greece
[3] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Via Venezian 1, I-20133 Milan, Italy
[4] Univ Milan, Dept Oncol & Hematooncol, I-20122 Milan, Italy
[5] Med Oncol Santa Croce & Carle Gen Hosp Cuneo, I-12100 Cuneo, Italy
[6] IRCCS Osped Policlin San Martino, I-16132 Genoa, Italy
[7] Azienda Osped Univ Careggi, Radiat Oncol, I-50134 Florence, Italy
[8] European Inst Oncol IRCCS, Dept Med Oncol Urogenital & Head & Neck Tumors Me, IEO, I-20141 Milan, Italy
[9] Univ Hosp Modena, Dept Hematol & Oncol, Med Oncol Unit, I-41125 Modena, Italy
[10] San Paolo Hosp, Med Oncol Unit, I-20142 Milan, Italy
[11] Univ Brescia, ASST Spedali Civili, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, I-25123 Brescia, Italy
关键词
immunotherapy; nasopharyngeal cancer; EBV DNA; nonendemic region; ANTITUMOR-ACTIVITY; PHASE-II; RECURRENT; CHEMOTHERAPY; MULTICENTER; PEMBROLIZUMAB; CAMRELIZUMAB; BIOMARKERS; CANCER; SAFETY;
D O I
10.3390/cells11010032
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.
引用
收藏
页数:10
相关论文
共 50 条
[31]   Toxicities from immunotherapy: From clinical trials to real-world clinical practice [J].
Riveiro-Barciela, Mar ;
Trallero-Araguas, Ernesto ;
Martinez-Valle, Fernando .
MEDICINA CLINICA, 2020, 155 (12) :541-547
[32]   Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients [J].
Gerald, Thomas ;
Margulis, Vitaly ;
Meng, Xiaosong ;
Bagrodia, Aditya ;
Cole, Suzanne ;
Qin, Qian ;
Call, S. Greg ;
Mauer, Elizabeth ;
Lotan, Yair ;
Woldu, Solomon L. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (03) :148.e17-148.e24
[33]   A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence [J].
Fang, Yixin ;
Wang, Hongwei ;
He, Weili .
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (04) :749-757
[34]   Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients [J].
Prelaj, Arsela ;
Galli, Edoardo Gregorio ;
Miskovic, Vanja ;
Pesenti, Mattia ;
Viscardi, Giuseppe ;
Pedica, Benedetta ;
Mazzeo, Laura ;
Bottiglieri, Achille ;
Provenzano, Leonardo ;
Spagnoletti, Andrea ;
Marinacci, Roberto ;
De Toma, Alessandro ;
Proto, Claudia ;
Ferrara, Roberto ;
Brambilla, Marta ;
Occhipinti, Mario ;
Manglaviti, Sara ;
Galli, Giulia ;
Signorelli, Diego ;
Giani, Claudia ;
Beninato, Teresa ;
Pircher, Chiara Carlotta ;
Rametta, Alessandro ;
Kosta, Sokol ;
Zanitti, Michele ;
Di Mauro, Maria Rosa ;
Rinaldi, Arturo ;
Di Gregorio, Settimio ;
Antonia, Martinetti ;
Garassino, Marina Chiara ;
de Braud, Filippo G. M. ;
Restelli, Marcello ;
Lo Russo, Giuseppe ;
Ganzinelli, Monica ;
Trovo, Francesco ;
Pedrocchi, Alessandra Laura Giulia .
FRONTIERS IN ONCOLOGY, 2023, 12
[35]   Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data [J].
Shen, Li-Li ;
Zheng, Hua-Long ;
Zheng, Zhi-Wei ;
Xu, Bin-bin ;
Xue, Zhen ;
Jia-Lin, Qi-Yue ;
Chen, Qi-Yue ;
Xie, Jian-Wei ;
Li, Ping ;
Huang, Chang-Ming ;
Lin, Jian-Xian ;
Zheng, Chao-Hui .
GASTRIC CANCER, 2025,
[36]   Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy [J].
Elumalai, T. ;
Croxford, W. ;
Buijtenhuijs, B. ;
Conroy, R. ;
Sanderson, B. ;
Enting, D. ;
Aversa, C. ;
Doss, G. ;
Das, A. ;
Vasudev, N. S. ;
Kitetere, E. ;
Tolan, S. ;
Law, A. ;
Hoskin, P. ;
Mistry, H. ;
Choudhury, A. .
CLINICAL ONCOLOGY, 2022, 34 (10) :642-652
[37]   Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma [J].
Ohsawa, Manato ;
Hamai, Yoichi ;
Emi, Manabu ;
Ibuki, Yuta ;
Kurokawa, Tomoaki ;
Yoshikawa, Toru ;
Hirohata, Ryosuke ;
Kitasaki, Nao ;
Okada, Morihito .
FRONTIERS IN ONCOLOGY, 2023, 13
[38]   Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience [J].
Ranganathan, Sanjana ;
Riveros, Carlos ;
Xu, Jiaqiong ;
Hu, Siqi ;
Geng, Michael ;
Huang, Emily ;
Melchiode, Zachary ;
Zhang, Jun ;
Efstathiou, Eleni ;
Chan, Keith Syson ;
Wallis, Christopher J. D. ;
Sonpavde, Guru ;
Satkunasivam, Raj .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (09) :291e13-291e25
[39]   Immunotherapy-related hepatitis: real-world experience from a tertiary centre [J].
Cheung, Vincent ;
Gupta, Tarun ;
Payne, Miranda ;
Middleton, Mark R. ;
Collier, Jane D. ;
Simmons, Alison ;
Klenerman, Paul ;
Brain, Oliver ;
Cobbold, Jeremy F. .
FRONTLINE GASTROENTEROLOGY, 2019, 10 (04) :364-371
[40]   Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study [J].
Shi, Xiaoqiong ;
Zhu, Minhui ;
He, Jianqiao ;
Gao, Yingna ;
Ma, Yi ;
Li, Haopu ;
Yu, Guoning ;
Zhao, Lin ;
Zheng, Hongliang ;
Zhang, Caiyun .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2025,